Literature DB >> 23896865

SEOM clinical guidelines for the treatment of advanced colorectal cancer 2013.

E Casado-Saenz1, J Feliu, M A Gomez-España, A Sanchez-Gastaldo, R Garcia-Carbonero.   

Abstract

Colorectal cancer (CRC) is the most common malignant tumor in Western countries. Despite efforts made to implement screening programmes for early detection and treatment, still half of the patients present or will eventually develop distant metastasis. Management of advanced CRC should be discussed within an experienced multidisciplinary team, to adequately select the most appropriate systemic therapeutic option, as well as the optimal way to integrate it with surgical procedures when indicated. Disease localization and extent, resectability of primary and metastatic disease, tumor biology and dynamics, clinical symptoms, personal preferences and patient's ability to tolerate intensive chemotherapy or extensive surgical procedures are the key factors to properly design a customized treatment plan. The aim of the current manuscript is to provide synthetic practical guidelines regarding therapeutic options for advanced CRC.

Entities:  

Mesh:

Year:  2013        PMID: 23896865     DOI: 10.1007/s12094-013-1082-5

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  26 in total

1.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Authors:  Marc Peeters; Timothy Jay Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Valentina Tzekova; Simon Collins; Kelly S Oliner; Alan Rong; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study.

Authors:  C Bokemeyer; I Bondarenko; J T Hartmann; F de Braud; G Schuch; A Zubel; I Celik; M Schlichting; P Koralewski
Journal:  Ann Oncol       Date:  2011-01-12       Impact factor: 32.976

3.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

4.  Cancer incidence and mortality in Spain: estimates and projections for the period 1981-2012.

Authors:  M J Sánchez; T Payer; R De Angelis; N Larrañaga; R Capocaccia; C Martinez
Journal:  Ann Oncol       Date:  2010-05       Impact factor: 32.976

5.  Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.

Authors:  Jaafar Bennouna; Javier Sastre; Dirk Arnold; Pia Österlund; Richard Greil; Eric Van Cutsem; Roger von Moos; Jose Maria Viéitez; Olivier Bouché; Christophe Borg; Claus-Christoph Steffens; Vicente Alonso-Orduña; Christoph Schlichting; Irmarie Reyes-Rivera; Belguendouz Bendahmane; Thierry André; Stefan Kubicka
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

6.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.

Authors:  Eric Van Cutsem; Claus-Henning Köhne; István Láng; Gunnar Folprecht; Marek P Nowacki; Stefano Cascinu; Igor Shchepotin; Joan Maurel; David Cunningham; Sabine Tejpar; Michael Schlichting; Angela Zubel; Ilhan Celik; Philippe Rougier; Fortunato Ciardiello
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

7.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Authors:  Alfredo Falcone; Sergio Ricci; Isa Brunetti; Elisabetta Pfanner; Giacomo Allegrini; Cecilia Barbara; Lucio Crinò; Giovanni Benedetti; Walter Evangelista; Laura Fanchini; Enrico Cortesi; Vincenzo Picone; Stefano Vitello; Silvana Chiara; Cristina Granetto; Gianfranco Porcile; Luisa Fioretto; Cinzia Orlandini; Michele Andreuccetti; Gianluca Masi
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

8.  Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Authors:  Leonard B Saltz; Stephen Clarke; Eduardo Díaz-Rubio; Werner Scheithauer; Arie Figer; Ralph Wong; Sheryl Koski; Mikhail Lichinitser; Tsai-Shen Yang; Fernando Rivera; Felix Couture; Florin Sirzén; Jim Cassidy
Journal:  J Clin Oncol       Date:  2008-04-20       Impact factor: 44.544

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

Authors:  Axel Grothey; Eric Van Cutsem; Alberto Sobrero; Salvatore Siena; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Josep Tabernero; Takayuki Yoshino; Heinz-Josef Lenz; Richard M Goldberg; Daniel J Sargent; Frank Cihon; Lisa Cupit; Andrea Wagner; Dirk Laurent
Journal:  Lancet       Date:  2012-11-22       Impact factor: 79.321

View more
  8 in total

1.  SEOM guidelines 2013: a response to the needs of Spanish oncologists.

Authors:  J J Cruz-Hernández; C A Rodríguez
Journal:  Clin Transl Oncol       Date:  2013-08-08       Impact factor: 3.405

2.  Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram.

Authors:  A Fernandez Montes; F Vazquez Rivera; N Martinez Lago; M Covela Rúa; A Cousillas Castiñeiras; P Gonzalez Villarroel; J de la Cámara Gómez; J C Méndez Méndez; M Salgado Fernández; S Candamio Folgar; M Reboredo López; M Carmona Campos; E Gallardo Martín; M Jorge Fernández; M L Pellón Augusto; L París Bouzas; J García Gómez
Journal:  Clin Transl Oncol       Date:  2019-05-09       Impact factor: 3.405

3.  SEOM/SERAM consensus statement on radiological diagnosis, response assessment and follow-up in colorectal cancer.

Authors:  R García-Carbonero; R Vera; F Rivera; E Parlorio; M Pagés; E González-Flores; C Fernández-Martos; M Á Corral; R Bouzas; F Matute
Journal:  Clin Transl Oncol       Date:  2016-05-20       Impact factor: 3.405

Review 4.  Aflibercept: A Review in Metastatic Colorectal Cancer.

Authors:  Yahiya Y Syed; Kate McKeage
Journal:  Drugs       Date:  2015-08       Impact factor: 9.546

5.  Gene expression profile predictive of response to chemotherapy in metastatic colorectal cancer.

Authors:  Purificacion Estevez-Garcia; Fernando Rivera; Sonia Molina-Pinelo; Marta Benavent; Javier Gómez; Maria Luisa Limón; Maria Dolores Pastor; Julia Martinez-Perez; Luis Paz-Ares; Amancio Carnero; Rocio Garcia-Carbonero
Journal:  Oncotarget       Date:  2015-03-20

6.  Efficacy and safety of aflibercept in metastatic colorectal cancer pretreated with bevacizumab: A report of five cases.

Authors:  Julia Alcaide; Mayte Delgado; Marta Legerén; José Miguel Jurado; Isabel Blancas; Teresa Pereda; Jorge López; Margarita Garrido; María J Sánchez; José L García; Antonio Rueda
Journal:  Oncol Lett       Date:  2016-08-30       Impact factor: 2.967

7.  SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015.

Authors:  E Aranda; J Aparicio; V Alonso; X Garcia-Albeniz; P Garcia-Alfonso; R Salazar; M Valladares; R Vera; J M Vieitez; R Garcia-Carbonero
Journal:  Clin Transl Oncol       Date:  2015-12-15       Impact factor: 3.405

8.  Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy.

Authors:  Jie Yang; Yuan Lin; Ying Huang; Jing Jin; Shuangmei Zou; Xiaolong Zhang; Hongmin Li; Ting Feng; Jinna Chen; Zhixiang Zuo; Jian Zheng; Yexiong Li; Ge Gao; Chen Wu; Wen Tan; Dongxin Lin
Journal:  Theranostics       Date:  2019-09-21       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.